Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2010 | 5 | 4 | 520-526
Tytuł artykułu

Fibrinogen and antithrombin in hematological patients with neutropenic fever

Treść / Zawartość
Warianty tytułu
Języki publikacji
The value of plasma fibrinogen and antithrombin as predictors of severe sepsis was investigated in 69 adult hematological patients, who had altogether 93 periods of neutropenic fever. Patients had either acute myeloid leukemia or had received a high dose of chemotherapy supported by autologous stem cell transplantation. In febrile periods with severe sepsis, the median fibrinogen concentration at the start of the fever was significantly higher (5.0 g/L) than that without severe sepsis (4.5 g/L) (p=0.009). Normal plasma fibrinogen could rule out a group of patients with severe sepsis at the beginning of the fever. The antithrombin activity decreased, both in fever periods with severe sepsis and in those without. The decrease in antithrombin activity was found to be greater in fever periods characterized by severe sepsis. In conclusion, elevated plasma fibrinogen and constantly decreasing antithrombin were shown to be linked to the development of severe sepsis.

Opis fizyczny
  • Department of Medicine, Kuopio University Hospital, P.B. 1777, 70211, Kuopio, Finland
  • Department of Medicine, Kuopio University Hospital, P.B. 1777, 70211, Kuopio, Finland
  • Department of Medicine, Kuopio University Hospital, P.B. 1777, 70211, Kuopio, Finland
  • [1] Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E, Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences, Leuk Lymphoma, 2008, 49, 495–501[Crossref]
  • [2] Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E, Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome, Scand J Infect Dis, 2009, 41, 14–20[Crossref]
  • [3] Krüger W, Rüssmann B, Kröger N, Salomon C, Ekopf N, Elsner H-A, et al., Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases, Bone Marrow Transplant, 1999, 23, 589–597
  • [4] Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, et al., Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients, Eur J Haematol, 2006, 76, 245–250
  • [5] Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson L-O, et al., Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia, Scand J Infect Dis, 2004, 36, 365–371[Crossref]
  • [6] Esmon CT, The interactions between inflammation and coagulation, Br J Haematol, 2005, 131, 417–430[Crossref]
  • [7] Levi M, Keller TT, Van Gorp E, Ten Cate H, Infection and inflammation and the coagulation system, Cardiovasc Res, 2003, 60, 26–39[Crossref]
  • [8] Schouten M, Wiersinga J, Levi M, Van der Poll T, Inflammation, endothelium, and coagulation in sepsis, J Leukoc Biol, 2008, 83, 536–545[Crossref]
  • [9] Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast, J, Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients, Blood, 1996, 88, 881–886
  • [10] Zeerleder S, Hack CE, Wuillemin WA, Disseminated intravascular coagulation in sepsis, Chest, 2005, 128, 2864–2875[Crossref]
  • [11] Fourier F, Chopin C, Huart J-J, Runge I, Caron C, Goudemand J, Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation, Chest, 1993, 104, 882–888[Crossref]
  • [12] Hunault-Berger M, Chevallier P, Delain M, Bulabois C-E, Bologna S, Bernard M, et al., Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study, Haematologica, 2008, 93, 1488–1494[Crossref][WoS]
  • [13] Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al., 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 2002, 34, 730–751[Crossref]
  • [14] Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine., Chest, 1992, 101, 1644–1655[Crossref]
  • [15] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al., 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference, Crit Care Med, 2003, 31, 1250–1256[Crossref]
  • [16] Delves PJ, Roitt IM, The immune system, N Engl J Med, 2000, 343, 37–49[Crossref]
  • [17] Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC, Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis, Crit Care, 2006, 10, 160–165[Crossref]
  • [18] Falanga A, Zacharski L, Deep vein thrombosis in cancer: the scale of the problem and approaches to management, Ann Oncol, 2005, 16, 696–701[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.